A mouse interferon alpha gene (MuIFN-alpha 10) was isolated from a BALB/c cosmid genomic library. The gene was located on a 1.8 kb HindIII fragment and a 5.1 kb EcoRI fragment. The coding region and parts of the 5' and 3' non-coding regions were sequenced. The results showed that the MuIFN-alpha 10 gene encoded a protein of 167 amino acids. Like most other MuIFN-alpha species it contained a putative N-glycosylation site at amino acid positions 78 to 80. It also possessed cysteine residues at positions 1, 29, 86, 99 and 129. In the signal peptide, in addition to cysteine 21, which is present in all MuIFN-alpha species sequenced so far, a cysteine was found at position 22. At the amino acid level MuIFN-alpha 10 showed strong homology to MuIFN-alpha 1 (only 15 out of 167 amino acids were different). The MuIFN-alpha 10 gene was transiently expressed in monkey COS cells under the direction of the simian virus 40 early promoter. The protein product secreted by COS cells was equally active on mouse (L929) and hamster (CHO) cells. However, as compared to MuIFN-alpha 1 and MuIFN-alpha 4 the specific activity on mouse cells of the protein was 10- to 100-fold lower. To find out which region of its structure was responsible for this low activity, hybrids of the genes encoding MuIFN-alpha 10 and MuIFN-alpha 1 were constructed using the two common XmmI sites which correspond to positions between amino acids 67 and 68 and 123 and 124, respectively. The data showed that hybrid constructs which were MuIFN-alpha 1-like from amino acid 68 or MuIFN-alpha 10-like from position 124 to the C terminus possessed high antiviral activity. Other hybrid constructs were hardly active at all. This implied that the amino acid 68 to 123 region was mainly responsible for the low antiviral activity of MuIFN-alpha 10. In this part of the molecule MuIFN-alpha 1 and MuIFN-alpha 10 differed in only five amino acids. A serine at position 110 and a valine at 85 were unique to MuIFN-alpha 10 as compared to all known MuIFN-alpha and human IFN-alpha subspecies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1099/0022-1317-69-1-67 | DOI Listing |
J Interferon Cytokine Res
March 2002
Department of Biotechnology, Kyoto Institute of Technology, Matsugasaki, Kyoto 606-8585, Japan.
Interferon-tau (IFN-tau) is a member of the type I IFN family. Although its distribution is restricted to ruminants, IFN-tau is active against cells of humans and mice. It has been reported that oral administration of ovine IFN-tau (OvIFN-tau) prevents both acute and chronic relapsing forms of murine experimental allergic encephalomyelitis (EAE).
View Article and Find Full Text PDFJ Interferon Cytokine Res
September 2001
Department of Microbiology, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, Perth, Western Australia, 6009, Australia.
The beneficial effects of low-dose orally administered type I interferon (LDOA IFN) have been demonstrated in various animal models of disease and in some human clinical trials. The mechanisms by which LDOA IFN therapy has its effects, however, remain to be established. In the present study, groups of mice were administered 10 IU murine IFN-alpha/beta (MuIFN-alpha/beta) orally for 7 days.
View Article and Find Full Text PDFJ Interferon Cytokine Res
August 2001
Laboratory of Viral Oncology, UPR 9045 CNRS, Institut Andre Lwoff/IFR 2249, 7 rue Guy Moquet, 94801 Villejuif, France.
Oromucosal (o.m.) administration of interferon-alpha (IFN-alpha) during either allergic sensitization (days 0-6) or the hypersensitive response (days 11 and 12) or both periods caused a dose-dependent reduction in allergen-specific IgE production and allergen-induced eosinophil recruitment in mice sensitized to ragweed pollen, a common allergen in humans.
View Article and Find Full Text PDFAnticancer Res
March 2001
Department of Anatomy, H. Lee Moffitt Cancer Center and Research Institute, Neuro-Oncology Program and the Neuroscience Program, University of South Florida, College of Medicine, 12901 Bruce B. Downs Blvd., Tampa, Fl. 33612, USA.
We have previously reported that invasiveness of mouse glioma G-26, which expresses CD44 adhesion molecule, was inhibited in vitro following treatment with anti-CD44 antibody or mouse interferon alpha/beta (MuIFN alpha/beta). Here, we evaluated whether the expression of transmembrane CD44 adhesion molecule and/or secretion of extracellular matrix metalloproteinases (MMPs) were affected when glioma cell invasion was inhibited. Flow cytometric evaluation of CD44 adhesion molecule expression in G-26 glioma using anti-CD44 antibody, confirmed that G-26 cells were CD44+.
View Article and Find Full Text PDFJ Interferon Cytokine Res
February 1999
Laboratory of Viral Oncology, UPR 9045 CNRS, Institut de Recherches sur le Cancer/IFR Y1221, Villejuif, France.
Oromucosal administration of [125I]-labeled recombinant human interferon-alpha1-8 (IFN-alpha1-8), which is biologically active in the mouse, resulted in readily detectable levels of radioactivity in the serum of animals within 5 min. Biologically active IFN could not be detected in the serum at any time after oromucosal administration, however, and SDS-PAGE analysis showed that the material present in the serum was of low molecular weight and most probably reflected absorption of degradation products following digestion of IFN in the stomach and small intestine. Furthermore, oromucosal administration of murine IFN-alpha/beta (MuIFN-alpha/beta) had no significant effect on the expression of IFN-responsive genes in either peripheral blood mononuclear cells or splenic lymphocytes even though in the same animals IFN treatment activated gene transcription locally in the lymphoid tissue of the oropharyngeal cavity and caused a marked systemic antiviral activity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!